Evotec SE (EVO)
USD 4.33
(-9.41%)
USD 4.33
(-9.41%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -47.5 Million EUR | -957.05% |
| 2022 | 12.49 Million EUR | -54.26% |
| 2021 | 27.32 Million EUR | -43.7% |
| 2020 | 48.52 Million EUR | -22.48% |
| 2019 | 62.59 Million EUR | -19.19% |
| 2018 | 77.46 Million EUR | 106.6% |
| 2017 | 37.49 Million EUR | 19.63% |
| 2016 | 31.34 Million EUR | 169.26% |
| 2015 | 11.64 Million EUR | 282.42% |
| 2014 | -6.38 Million EUR | 70.11% |
| 2013 | -21.35 Million EUR | -566.8% |
| 2012 | -3.2 Million EUR | -161.49% |
| 2011 | 5.2 Million EUR | 203.62% |
| 2010 | 1.71 Million EUR | 104.05% |
| 2009 | -42.29 Million EUR | 42.22% |
| 2008 | -73.21 Million EUR | -25.97% |
| 2007 | -58.11 Million EUR | -58.08% |
| 2006 | -36.76 Million EUR | -11.52% |
| 2005 | -32.96 Million EUR | -8.93% |
| 2004 | -30.26 Million EUR | 8.71% |
| 2003 | -33.15 Million EUR | -38.64% |
| 2002 | -23.91 Million EUR | -87.72% |
| 2001 | -12.73 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -43.23 Million EUR | -281.5% |
| 2024 Q1 | -27.42 Million EUR | -11.35% |
| 2023 Q1 | 12.51 Million EUR | -66.79% |
| 2023 Q2 | -36.28 Million EUR | -389.96% |
| 2023 Q4 | -24.62 Million EUR | -102.05% |
| 2023 FY | -107.08 Million EUR | -957.05% |
| 2023 Q3 | -12.18 Million EUR | 66.42% |
| 2022 Q3 | -13.52 Million EUR | -258.86% |
| 2022 Q1 | 125.36 Million EUR | 738.93% |
| 2022 Q2 | -3.77 Million EUR | -103.01% |
| 2022 Q4 | 37.68 Million EUR | 378.56% |
| 2022 FY | 12.49 Million EUR | -54.26% |
| 2021 FY | 27.32 Million EUR | -43.7% |
| 2021 Q2 | 1.53 Million EUR | -77.32% |
| 2021 Q1 | 6.77 Million EUR | -48.8% |
| 2021 Q3 | 17.73 Million EUR | 1054.07% |
| 2021 Q4 | 14.94 Million EUR | -15.76% |
| 2020 FY | 48.52 Million EUR | -22.48% |
| 2020 Q4 | 13.23 Million EUR | -19.13% |
| 2020 Q3 | 16.36 Million EUR | 480.05% |
| 2020 Q2 | 2.82 Million EUR | -82.47% |
| 2020 Q1 | 16.09 Million EUR | -0.46% |
| 2019 Q1 | 19.05 Million EUR | 6.2% |
| 2019 Q4 | 16.16 Million EUR | -27.78% |
| 2019 Q3 | 22.38 Million EUR | 349.76% |
| 2019 Q2 | 4.97 Million EUR | -73.88% |
| 2019 FY | 62.59 Million EUR | -19.19% |
| 2018 Q2 | 15.15 Million EUR | 132.11% |
| 2018 Q4 | 17.94 Million EUR | -52.56% |
| 2018 FY | 77.46 Million EUR | 106.6% |
| 2018 Q1 | 6.53 Million EUR | -43.88% |
| 2018 Q3 | 37.82 Million EUR | 149.54% |
| 2017 Q3 | 7.62 Million EUR | -10.57% |
| 2017 FY | 37.49 Million EUR | 19.63% |
| 2017 Q4 | 11.63 Million EUR | 52.67% |
| 2017 Q2 | 8.52 Million EUR | -12.21% |
| 2017 Q1 | 9.71 Million EUR | -11.45% |
| 2016 Q2 | 5.64 Million EUR | 105.72% |
| 2016 Q3 | 11.98 Million EUR | 112.35% |
| 2016 Q4 | 10.96 Million EUR | -8.52% |
| 2016 FY | 31.34 Million EUR | 169.26% |
| 2016 Q1 | 2.74 Million EUR | 525.43% |
| 2015 Q2 | 16.22 Million EUR | 591.58% |
| 2015 Q4 | -645 Thousand EUR | -1.26% |
| 2015 FY | 11.64 Million EUR | 282.42% |
| 2015 Q1 | -3.3 Million EUR | -240.78% |
| 2015 Q3 | -637 Thousand EUR | -103.93% |
| 2014 Q2 | -83 Thousand EUR | 97.62% |
| 2014 Q4 | 2.34 Million EUR | 145.43% |
| 2014 FY | -6.38 Million EUR | 70.11% |
| 2014 Q1 | -3.48 Million EUR | 79.65% |
| 2014 Q3 | -5.16 Million EUR | -6116.87% |
| 2013 Q3 | 162 Thousand EUR | 109.6% |
| 2013 Q2 | -1.68 Million EUR | 37.89% |
| 2013 Q1 | -2.71 Million EUR | 55.27% |
| 2013 FY | -21.35 Million EUR | -566.8% |
| 2013 Q4 | -17.11 Million EUR | -10661.73% |
| 2012 Q1 | -1.28 Million EUR | 70.16% |
| 2012 Q3 | 1.53 Million EUR | -41.38% |
| 2012 Q4 | -6.07 Million EUR | -495.06% |
| 2012 FY | -3.2 Million EUR | -161.49% |
| 2012 Q2 | 2.62 Million EUR | 303.41% |
| 2011 Q3 | 8.6 Million EUR | 397.11% |
| 2011 Q1 | -810 Thousand EUR | -215.55% |
| 2011 Q4 | -4.31 Million EUR | -150.19% |
| 2011 FY | 5.2 Million EUR | 203.62% |
| 2011 Q2 | 1.73 Million EUR | 313.7% |
| 2010 Q3 | 672 Thousand EUR | -63.0% |
| 2010 Q1 | -1.47 Million EUR | 84.26% |
| 2010 FY | 1.71 Million EUR | 104.05% |
| 2010 Q2 | 1.81 Million EUR | 223.2% |
| 2010 Q4 | 701 Thousand EUR | 4.32% |
| 2009 Q2 | -8.86 Million EUR | 56.21% |
| 2009 Q3 | -3.81 Million EUR | 56.98% |
| 2009 Q4 | -9.36 Million EUR | -145.53% |
| 2009 FY | -42.29 Million EUR | 42.22% |
| 2009 Q1 | -20.24 Million EUR | 46.74% |
| 2008 Q4 | -38.02 Million EUR | -357.8% |
| 2008 FY | -73.21 Million EUR | -25.97% |
| 2008 Q3 | -8.3 Million EUR | 26.17% |
| 2008 Q2 | -11.24 Million EUR | 21.77% |
| 2008 Q1 | -14.37 Million EUR | -459.1% |
| 2007 Q4 | 4 Million EUR | 134.47% |
| 2007 Q3 | -11.61 Million EUR | -73.92% |
| 2007 Q2 | -6.67 Million EUR | 0.0% |
| 2007 Q1 | - EUR | 100.0% |
| 2007 FY | -58.11 Million EUR | -58.08% |
| 2006 Q3 | -5.85 Million EUR | -28.36% |
| 2006 FY | -36.76 Million EUR | -11.52% |
| 2006 Q4 | -11.63 Million EUR | -98.55% |
| 2006 Q1 | -5.88 Million EUR | -13.95% |
| 2006 Q2 | -4.56 Million EUR | 22.48% |
| 2005 Q4 | -5.16 Million EUR | 0.0% |
| 2005 Q1 | -7.7 Million EUR | -31.67% |
| 2005 Q2 | -8.24 Million EUR | -6.96% |
| 2005 Q3 | - EUR | 100.0% |
| 2005 FY | -32.96 Million EUR | -8.93% |
| 2004 Q2 | -8.06 Million EUR | -14.48% |
| 2004 FY | -30.26 Million EUR | 8.71% |
| 2004 Q1 | -7.04 Million EUR | -2.92% |
| 2004 Q3 | - EUR | 100.0% |
| 2004 Q4 | -5.85 Million EUR | 0.0% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | -5.95 Million EUR | 0.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | -33.15 Million EUR | -38.64% |
| 2003 Q4 | -6.84 Million EUR | -14.96% |
| 2002 FY | -23.91 Million EUR | -87.72% |
| 2001 FY | -12.73 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Theratechnologies Inc. | -10.62 Million USD | -347.041% |
| Harrow Health, Inc. | 580 Thousand USD | 8290.862% |
| Dynavax Technologies Corporation | -37.02 Million USD | -28.3% |
| Biofrontera Inc. | -22.67 Million USD | -109.494% |
| Cronos Group Inc. | -81.37 Million USD | 41.62% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -910.572% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 122.727% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -21.337% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 476.085% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -664.907% |
| Radius Health, Inc. | -3.92 Million USD | -1110.369% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -1247.038% |
| DURECT Corporation | -36.88 Million USD | -28.801% |
| ProPhase Labs, Inc. | -21.61 Million USD | -119.808% |
| Safety Shot Inc | -12.18 Million USD | -289.908% |
| Phibro Animal Health Corporation | 53.31 Million USD | 189.106% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1788.783% |
| Alvotech | -354.86 Million USD | 86.612% |
| Assertio Holdings, Inc. | -243.53 Million USD | 80.493% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -801.632% |
| Rockwell Medical, Inc. | -6.67 Million USD | -612.249% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -892.77% |
| Procaps Group S.A. | 52.32 Million USD | 190.794% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 70.193% |
| SCYNEXIS, Inc. | 72.66 Million USD | 165.375% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -804.206% |
| Viatris Inc. | 766.2 Million USD | 106.2% |
| OptiNose, Inc. | -22.74 Million USD | -108.84% |
| SIGA Technologies, Inc. | 83.62 Million USD | 156.812% |
| Tilray Brands, Inc. | -174.74 Million USD | 72.814% |
| PetIQ, Inc. | 60.01 Million USD | 179.159% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -892.77% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 118.935% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -995.561% |
| Alimera Sciences, Inc. | -1.47 Million USD | -3129.572% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 128.454% |
| Silver Spike Investment Corp. | 7.34 Million USD | 747.225% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -706.245% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 479.297% |
| Journey Medical Corporation | -2.07 Million USD | -2191.703% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -248.871% |
| Alpha Teknova, Inc. | -35.56 Million USD | -33.585% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -204.649% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 609.131% |
| PainReform Ltd. | -9.58 Million USD | -395.691% |
| Cosmos Health Inc. | -21.83 Million USD | -117.61% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 65.537% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -457.398% |
| Embecta Corp. | 221.5 Million USD | 121.448% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -902.95% |
| Talphera, Inc. | -16.88 Million USD | -181.29% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 154.185% |
| Incannex Healthcare Limited | -30.04 Million USD | -58.141% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -136.942% |
| Shineco, Inc. | -17.06 Million USD | -178.374% |
| Procaps Group, S.A. | 38.97 Million USD | 221.897% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 201.141% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -214.574% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 113.028% |
| Alvotech | -354.86 Million USD | 86.612% |
| Hempacco Co., Inc. | -8.81 Million USD | -439.1% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 188.875% |
| Bright Green Corporation | -8.89 Million USD | -434.304% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 69.461% |
| Kamada Ltd. | 10.06 Million USD | 572.049% |
| Indivior PLC | -4 Million USD | -1087.675% |
| Evoke Pharma, Inc. | -7.43 Million USD | -539.318% |
| Flora Growth Corp. | -50.35 Million USD | 5.654% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -136.942% |
| Evolus, Inc. | -49.23 Million USD | 3.506% |
| HUTCHMED (China) Limited | 18.37 Million USD | 358.541% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 124.117% |
| Akanda Corp. | -10.05 Million USD | -372.642% |